0001907867-22-000001.txt : 20220131 0001907867-22-000001.hdr.sgml : 20220131 20220131133417 ACCESSION NUMBER: 0001907867-22-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220131 DATE AS OF CHANGE: 20220131 EFFECTIVENESS DATE: 20220131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: YAP Therapeutics Inc CENTRAL INDEX KEY: 0001907867 IRS NUMBER: 813388425 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-431534 FILM NUMBER: 22572513 BUSINESS ADDRESS: STREET 1: 26051 MERIT CIRCLE, SUTIE 102 CITY: LAGUNA HILLS STATE: CA ZIP: 92653 BUSINESS PHONE: 949-348-1188 MAIL ADDRESS: STREET 1: 26051 MERIT CIRCLE, SUTIE 102 CITY: LAGUNA HILLS STATE: CA ZIP: 92653 D 1 primary_doc.xml X0708 D LIVE 0001907867 YAP Therapeutics Inc 26051 MERIT CIRCLE, SUITE 102 LAGUNA HILLS CA CALIFORNIA 92653 949-348-1188 DELAWARE None None Corporation true Olav B. Bergheim 26051 Merit Circle, Suite 102 Laguna Hills CA CALIFORNIA 92653 Executive Officer Director Andrew Wade 26051 Merit Circle, Suite 102 Laguna Hills CA CALIFORNIA 92653 Executive Officer Biotechnology Decline to Disclose 06b false 2022-01-12 false true true Series B Preferred Stock and the Common Stock issuable upon conversion thereof. false 0 30063589 30063589 0 false 6 0 0 0 false YAP Therapeutics Inc /s/ Andrew Wade Andrew Wade Chief Financial Officer 2022-01-31